Profile | GDS2987 / GI_28144896-A |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 16.7 | 50 |
GSM215244 | HMVEC_vehicle_rep2 | 10.6 | 27 |
GSM215253 | HMVEC_vehicle_rep3 | ||
GSM215254 | HMVEC_atorvastatin_rep1 | ||
GSM215282 | HMVEC_atorvastatin_rep3 | ||
GSM215344 | HMVEC_atorvastatin_rep2 | ||
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | ||
GSM215294 | HMVEC_SLx2119_rep1 | 0.4 | 1 |
GSM215295 | HMVEC_SLx2119_rep2 | ||
GSM215296 | HMVEC_SLx2119_rep3 | ||
GSM215297 | PASMC_vehicle_rep1 | 67.3 | 67 |
GSM215298 | PASMC_vehicle_rep2 | 138.1 | 77 |
GSM215310 | PASMC_vehicle_rep3 | 199.7 | 81 |
GSM215311 | PASMC_atorvastatin_rep1 | 102.7 | 75 |
GSM215312 | PASMC_atorvastatin_rep2 | 61.3 | 65 |
GSM215313 | PASMC_atorvastatin_rep3 | 76.1 | 69 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 110.1 | 75 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 127.7 | 77 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 109.6 | 75 |
GSM215327 | PASMC_SLx2119_rep1 | 177.5 | 80 |
GSM215328 | PASMC_SLx2119_rep2 | 127.3 | 77 |
GSM215329 | PASMC_SLx2119_rep3 | 199.2 | 81 |
GSM215330 | Fibroblasts_vehicle_rep1 | 17.6 | 38 |
GSM215331 | Fibroblasts_vehicle_rep2 | ||
GSM215332 | Fibroblasts_vehicle_rep3 | 20.2 | 53 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 5.7 | 15 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 12.2 | 33 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 10.4 | 26 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 12.2 | 38 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 38.7 | 66 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 21.7 | 51 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 31.2 | 62 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 17.7 | 45 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 16.7 | 40 |